GRI Bio (GRI Bio) Short-Term Debt & Capital Lease Obligation : $0.04 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is GRI Bio Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. GRI Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.04 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. GRI Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.11 Mil.

GRI Bio Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for GRI Bio's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GRI Bio Short-Term Debt & Capital Lease Obligation Chart

GRI Bio Annual Data

Trend

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

3.55

0.66

0.01

GRI Bio Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial					-	0.04	0.03	0.01	0.04

GRI Bio Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

GRI Bio Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of GRI Bio's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

GRI Bio (GRI Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GRI Bio Inc (NAS:GRI) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

2223 Avenida De La Playa, Suite 208, La Jolla, CA, USA, 92037

Website

https://www.gribio.com

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis.

Executives

David Leslie Szekeres	director	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT, SUITE 210, SAN DIEGO CA 92121
Roelof Rongen	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Camilla V Simpson	director	20 ELAINE AVE., MILL VALLEY CA 94941
Albert Agro	officer: Chief Medical Officer	828 RICHMOND STREET WEST, TORONTO A6 M6J 1C9
Walter Marc Hertz	director, 10 percent owner, officer: Chief Executive Officer	2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Vipin Chaturvedi	officer: Chief Scientific Officer	2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Meenu Chhabra	director	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
Joseph E Payne	director	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Leanne M. Kelly	officer: Chief Financial Officer	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Marella Thorell	director	1226 CHARTER LANE, AMBLER PA 19002
Arcturus Therapeutics Holdings Inc.	10 percent owner	10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Penny Toren	officer: SVP, Regul Affairs & Prog Mgmt	C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Ofir Levi	director	C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Richard Ammer	director, 10 percent owner	C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Pharma Gmbh Salmon	10 percent owner	SANKT-JACOBS-STRASSE 90, CH-9002, BASEL V8 4052